Skip to main content
SpringerLink
Log in

Thyroid Cancer

  • Chapter
Neuroendocrine Tumours

Abstract

Thyroid cancer is a malignant neoplasm originating from follicular or parafollicular thyroid cells and is the most common endocrine malignancy which accounts for approximately 2 % of all cancers diagnosed worldwide. The female/male ratio is 2–3:1. The median age at diagnosis is 45–49 years in women and 65–69 years in men. There are four major types of thyroid carcinoma: papillary, follicular, medullary, and anaplastic carcinomas. The first two of them are classified together as differentiated thyroid carcinoma (DTC). External radiation exposure in the childhood or adolescent period is the only well-known etiologic factor for DTC. Family history is important, especially for medullary thyroid carcinoma. Histologic type, age at diagnosis, tumor size, extrathyroidal invasion, and distant metastases are the main prognostic factors of DTC. Surgery, 131I radioiodine (RAI) therapy, and TSH suppression therapy are the main therapeutic options for DTC. Serum thyroglobulin measurement is a good marker after total thyroidectomy and RAI ablation therapy to detect the residual/metastatic disease. Except for local-regional recurrences, lung, bone, and soft tissue metastases can be seen in decreasing order. Surgery and 131I RAI therapy are effective therapies in metastatic disease. In 131I RAI-refractory cases, chemotherapy and targeted therapies have been used in the treatment. Redifferentiation therapy is another therapeutic option in that situation. Anaplastic carcinoma is the most aggressive form of thyroid carcinoma, accounting for 1–3 % of all thyroid cancer. Median survival is less than 5 months after the time of diagnosis. Surgery, chemoradiotherapy, and chemotherapy have been used in the treatment of the disease. Clinical trials are ongoing with targeted drugs and biologic response modifiers. In this chapter, we will discuss the DTC and anaplastic thyroid carcinoma. Medullary thyroid carcinoma has been discussed in another chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sipos JA, Mazzaferri EI (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol 22:395–404

    CAS  Google Scholar 

  2. Kilfoy BA, Zheng T, Holford TR et al (2009) International pattern and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20:525–531

    PubMed Central  PubMed  Google Scholar 

  3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    PubMed  Google Scholar 

  4. Gilliland FD, Hunt WC, Morris DM et al (1997) Prognostic factors for thyroid carcinoma. A population based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573

    CAS  PubMed  Google Scholar 

  5. Sherman SI (2003) Thyroid carcinoma. Lancet 361:501–511

    PubMed  Google Scholar 

  6. Abu-Lebdeh HS, Menefee ME, Bible KC (2011) Thyroid and adrenal carcinomas. In: Skeel RT, Khleif SN (eds) Handbook of cancer chemotherapy. Wolters Kluwer, Philadelphia, pp 258–276

    Google Scholar 

  7. Busaidy NL, Habra MA, Vassilopoulou-Selin R (2011) Endocrine malignancies. In: Kantargian HM, Wolff RA, Koller CA (eds) The MD Anderson manual of medical oncology. Mc Graw Hill, New York, pp 1040–1056

    Google Scholar 

  8. Brown RL, de Sauza JA, Cohen EEW (2011) Thyroid cancer: burden of illness and management of disease. J Cancer 2:193–199

    PubMed Central  PubMed  Google Scholar 

  9. Cardis E, Kesminiene A, Ivanov V et al (2005) Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97:724–732

    PubMed  Google Scholar 

  10. Tucker MA, Jones PH, Boice JR Jr et al (1991) Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effect Study Group. Cancer Res 51:2885–2888

    CAS  PubMed  Google Scholar 

  11. Shore RE, Hildreth N, Dvoretsky P et al (1993) Thyroid cancer among persons given X-ray treatment in infancy for an enlarged thymus gland. Am J Epidemiol 137:1068–1080

    CAS  PubMed  Google Scholar 

  12. Ron E, Lubin JH, Shore RE et al (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259–277

    CAS  PubMed  Google Scholar 

  13. Hancock SL, Cox RS, Mc Dougall IR (1991) Thyroid disease after treatment Hodgkin’s disease. N Engl J Med 325:599–605

    CAS  PubMed  Google Scholar 

  14. Mc Dougall IR (1992) Radiation and the thyroid. In: Mc Dougall I (ed) Thyroid disease in clinical practice. Chapman&Hall, London, pp 304–321

    Google Scholar 

  15. Schneider AB, Sarne DH (2005) Long-term risk for thyroid cancer and other neoplasm after exposure to radiation. Nat Clin Pract Endocrinol Metab 1:82–91

    PubMed  Google Scholar 

  16. DeGroot L, Paloyan E (1973) Thyroid carcinoma and radiation. A Chicago endemic. JAMA 225:487–491

    CAS  PubMed  Google Scholar 

  17. Robbins J, Schneider AB (2000) Thyroid cancer following exposure to radioactive iodine. Rev Endocr Metab Disord 1:197–203

    CAS  PubMed  Google Scholar 

  18. Ron E (2007) Thyroid cancer incidence among people living in areas contaminated by radiation from the Chernobyl accident. Health Phys 93:502–511

    CAS  PubMed  Google Scholar 

  19. Furukawa K, Preston D, Funamoto S et al (2013) Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure. Int J Cancer 132:1222–1226

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Dicman PW, Holm LE, Lundell G et al (2003) Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 106:580–587

    Google Scholar 

  21. Horn-Ross PL, Morris JS, Lee M et al (2001) Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev 10:979–985

    CAS  PubMed  Google Scholar 

  22. Bosetti C, Kolonel L, Negri E et al (2001) A pooled analyses of case-control studies of thyroid cancer. VI. Fish and shellfish consumption. Cancer Causes Control 12:375–382

    CAS  PubMed  Google Scholar 

  23. Galanti MR, Ekbom A, Grimelus L, Yuen J (1997) Parental cancer and risk of papillary and follicular thyroid carcinoma. Br J Cancer 75:451–456

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Malchoff CD, Malchoff DM (2006) Familial nonmedullary thyroid carcinoma. Cancer Control 13:106–110

    PubMed  Google Scholar 

  25. You YN, Lakhani V, Wells SA Jr et al (2006) Medullary thyroid cancer. Surg Oncol Clin North Am 15:639–660

    Google Scholar 

  26. Negri E, Dal Maso L, Ron E et al (1999) A pooled analysis of case-control studies of thyroid cancer.II. Menstrual and reproductive factors. Cancer Causes Control 10:143–155

    CAS  PubMed  Google Scholar 

  27. Franceschi S, Preston-Martin S, Dal Maso L et al (1999) A pooled analysis of case-control studies of thyroid cancer IV. Benign thyroid diseases. Cancer Causes Control 10:583–595

    CAS  PubMed  Google Scholar 

  28. Eszlinger M, Krohn K, Hauptmann S et al (2008) Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 93:3286–3294

    CAS  PubMed  Google Scholar 

  29. Carling T, Udelsman R (2011) Thyroid tumors. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Cancer principles & practice of oncology, 9th edn. Wolters Kluwer, Philadelphia, pp 1457–1472

    Google Scholar 

  30. Winikoff SE, Brown CK (2005) Thyroid cancer. In: Brown CK, Rini BI, Connell PP, Posner MC (eds) Holland-Frei manual of cancer medicine. Pmph, USA, pp 258–274

    Google Scholar 

  31. Bounacer A, Wicker R, Caillou B et al (1997) High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15:1263–1273

    CAS  PubMed  Google Scholar 

  32. Fagin JA (2004) How thyroid tumors start and why it matters: Kinase mutant as targets for solid cancer pharmacotherapy. J Endocrinol 183:249–256

    CAS  PubMed  Google Scholar 

  33. Jhiang SM (2000) The RET proto-oncogene in human cancers. Oncogene 19:5590–5597

    CAS  PubMed  Google Scholar 

  34. Jhiang SM, Sagartz JE, Tong Q et al (1996) Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375–378

    CAS  PubMed  Google Scholar 

  35. Li X, Abdel-Mageed AB, Kandil E (2012) BRAF mutation in papillary thyroid cancer. Int J Clin Exp Med 5:310–315

    PubMed Central  CAS  PubMed  Google Scholar 

  36. Hannallah J, Rose J, Guerrero MA (2013) Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma Article ID:317487, 7 pages http://dx.doi.org/10.1155/2013/317487

  37. Lal G, O’Dorisio T, McDougal R, Weigel RJ (2008) Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, Mc Kenna WG (eds) Abeloff’s clinical oncology, 4th edn. Churchill Livingstone Elsevier, Philadelphia, pp 1271–1305

    Google Scholar 

  38. Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinoma. Cancer 52:1849–1855

    CAS  PubMed  Google Scholar 

  39. Carcangiu MI, Zampi G, Rosai J (1984) Poorly differentiated insular thyroid carcinoma. A reinterpretation of Langhans ‘Wuchernde Stroma’. Am J Surg Pathol 8:655–668

    CAS  PubMed  Google Scholar 

  40. Matias-Guiu X, Cuatrecasas M, Musulen E et al (1994) p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47:615–629

    Google Scholar 

  41. Jamshid F (2013) Thyroid nodules. The Bethesda classification for thyroid biopsies is effective for clinical management of thyroid nodules. Clin Thyroidology Patients 6:6–7

    Google Scholar 

  42. NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma Version 2. 2013. NCCN.org

    Google Scholar 

  43. Gharip H, Papini E, Paschke R (2010) AACE/AME/ETA thyroid nodule guidelines. Endocr Pract 2010:16–43

    Google Scholar 

  44. Cibas ES, Ali SZ (2009) The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol 132:658–665

    PubMed  Google Scholar 

  45. Bongiovanni M (2012) The Bethesda System for reporting thyroid cytopathology: a meta-analysis. Acta Cytol 56:333–339

    PubMed  Google Scholar 

  46. Nikiforov YE, Ohori NP, Hodak SP et al (2011) Impact of mutational testing on the diagnosis and management of patients cytologically indeterminate thyroid nodules: a prospective analyses of 1.056 FNA samples. J Clin Endocrinol Metab 96:3390–3397

    PubMed Central  CAS  PubMed  Google Scholar 

  47. Nikiforov YE, Steward DL, Robinson-Smith TM et al (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092–2098

    CAS  PubMed  Google Scholar 

  48. Ohori NP, Nikiforova MN, Schoedel KE et al (2010) Contribution of molecular testing to thyroid fine-needle aspiration cytology of follicular lesion of undetermined significance/atypia of undetermined significance. Cancer Cytopathol 118:17–23

    CAS  PubMed  Google Scholar 

  49. Hegedus L (2004) Clinical practise. The thyroid nodule. N Engl J Med 351:1764–1771

    PubMed  Google Scholar 

  50. Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guideline for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214

    PubMed  Google Scholar 

  51. Henry JF, Denizot A, Puccini M et al (1996) Early diagnosis of sporadic medullary cancers of the thyroid: value of systematic assay of calcitonin. Presse Med 25:1583–1588

    CAS  PubMed  Google Scholar 

  52. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428

    CAS  PubMed  Google Scholar 

  53. Staunton MD (1994) Thyroid cancer: a multivariate analysis on influence of treatment on long term survival. Eur J Surg Oncol 20:613–621

    CAS  PubMed  Google Scholar 

  54. Shah JP, Loree TR, Dharker D et al (1992) prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164:658–661

    CAS  PubMed  Google Scholar 

  55. Bilimoria KY, Bentrem DJ, Ko CY (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375–384

    PubMed Central  PubMed  Google Scholar 

  56. Hay ID, Grant CS, Taylor WF, Mc Conahey WM (1987) ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095

    CAS  PubMed  Google Scholar 

  57. Sherman SI, Brierley JD, Sperling M et al (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012–1021

    CAS  PubMed  Google Scholar 

  58. Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058

    CAS  PubMed  Google Scholar 

  59. Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York, pp 1–646

    Google Scholar 

  60. Görges R (2005) The changing of epidemiology of thyroid cancer. In: Biersack HJ, Grünwald F (eds) Thyroid cancer, 2nd edn. Springer, Berlin, pp 3–28

    Google Scholar 

  61. Shaha AR, Loree TR, Shah JP (1995) Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131–1136

    CAS  PubMed  Google Scholar 

  62. Lopez-Penabad L, Chiu AC, Hoff AO et al (2003) Prognostic factors in patients with Hurtle cell neoplasm of the thyroid. Cancer 97:1186–1194

    PubMed  Google Scholar 

  63. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985–1995. Cancer 83:2638–2648

    CAS  PubMed  Google Scholar 

  64. Baudin E, Travagli JP, Ropers J et al (1998) Microcarcinoma of the thyroid gland: the gustave-Roussy Institute experience. Cancer 83:553–559

    CAS  PubMed  Google Scholar 

  65. Roti E, Degli-Uberti EC, Bondanelli M, Braverman LE (2008) thyroid papillary microcarcinoma. A descriptive and meta-analysis study. Eur J Endocrinol 159:659–673

    CAS  PubMed  Google Scholar 

  66. Sanders EM Jr, LiVolsi VA, Brierley J et al (2007) An evidence-based review of poorly differentiated thyroid cancer. World J Surg 31:934–945

    PubMed  Google Scholar 

  67. Patel KN, Shaha AR (2006) Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13:119–128

    PubMed  Google Scholar 

  68. Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer. A 10 year follow-up study. J Clin Endocrinol Metab 93:682–687

    CAS  PubMed  Google Scholar 

  69. Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma.pathogenesis and emerging therapies. Clin Oncol 22:486–497

    CAS  Google Scholar 

  70. Emerick GT, Duh QY, Siperstein AE et al (1993) Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 72:3287–3295

    CAS  PubMed  Google Scholar 

  71. Coburn MC, Wanebo HJ (1992) prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 164:671–676

    CAS  PubMed  Google Scholar 

  72. Sellers M, Beenken S, Blankenship A et al (1992) Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg 164:578–581

    CAS  PubMed  Google Scholar 

  73. Voutilainen PE, Multanen MM, Leppaniemi AK et al (2001) Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 11:953–957

    CAS  PubMed  Google Scholar 

  74. Randolph GW, Duh QY, Heller KS et al (2012) The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22:1144–1152

    PubMed  Google Scholar 

  75. van Heerden JA, Hay ID, Goellner JR et al (1992) Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112:1130–1136

    PubMed  Google Scholar 

  76. Hay ID, Thompson GB, Grant CS et al (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885

    PubMed  Google Scholar 

  77. Lin JD, Chao TC, Huang MJ et al (1998) Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 21:77–81

    CAS  PubMed  Google Scholar 

  78. Rubino C, de Vathaire F, Dottorini ME et al (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644

    PubMed Central  CAS  PubMed  Google Scholar 

  79. Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518

    CAS  PubMed  Google Scholar 

  80. DeGroot LJ, Kaplan EL, Mc Cormick M, Straus FH (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424

    CAS  PubMed  Google Scholar 

  81. Samaan NA, Schultz PN, Hickey RC et al (1992) The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714–720

    CAS  PubMed  Google Scholar 

  82. Shaha AR, Shah JP, Loree TR (1997) Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474–476

    CAS  PubMed  Google Scholar 

  83. Sanders LE, Cady B (1998) Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133:419–425

    CAS  PubMed  Google Scholar 

  84. Nam-Goong IS, Kim HY, Gong G et al (2004) Ultrasonography-guided fine needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 60:21–28

    Google Scholar 

  85. Grebe SK, Hay ID (1996) Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5:43–63

    CAS  PubMed  Google Scholar 

  86. Scheumann GF, Gimm O, Wegener G et al (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559–567

    CAS  PubMed  Google Scholar 

  87. Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387

    PubMed  Google Scholar 

  88. Chow SM, Law SC, Chan JK et al (2003) Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 98:31–40

    PubMed  Google Scholar 

  89. Tisell LE, Nilsson B, Molne J et al (1996) Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 20:854–859

    CAS  PubMed  Google Scholar 

  90. Podnos YD, Smith D, Wagman LD et al (2005) The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 71:731–734

    PubMed  Google Scholar 

  91. Bilimoria KY, Zanocco K, Sturgeon C (2008) Impact of surgical treatment on outcomes for papillary thyroid cancer. Adv Surg 42:1–12

    PubMed  Google Scholar 

  92. Cavicchi O, Piccin O, Caliceti U et al (2007) Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg 137:654–658

    PubMed  Google Scholar 

  93. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr (1996) Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann Surg 223:472–478

    PubMed Central  PubMed  Google Scholar 

  94. Gimm O, Rath FW, Dralle H (1998) Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg 85:252–254

    CAS  PubMed  Google Scholar 

  95. Henry JF, Gramatica L, Denizot A et al (1998) Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 383:167–169

    CAS  PubMed  Google Scholar 

  96. Cheah WK, Arici C, Ituarte PH et al (2002) Complications of neck dissection for thyroid cancer. World J Surg 26:1013–1016

    PubMed  Google Scholar 

  97. White ML, Gauger PG, Doherty GM (2007) Central lymph node dissection in differentiated thyroid cancer. World J Surg 31:895–904

    PubMed  Google Scholar 

  98. Bonnet S, Hartl D, Leboulleux S et al (2009) Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94:1162–1167

    CAS  PubMed  Google Scholar 

  99. Sywak M, Cornford L, Roach P et al (2006) Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140:1000–1007

    PubMed  Google Scholar 

  100. Roh JL, Park JY, Park CI (2007) Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 245:604–610

    PubMed Central  PubMed  Google Scholar 

  101. Lee YS, Kim SW, Kim SW et al (2007) Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg 31:1954–1959

    PubMed  Google Scholar 

  102. Kozak OV, Muzichenko LV, Trembach AM et al (2006) First treatment activity and outcome of radioiodine therapy in thyroid cancer patients with metastases in lymph nodes: mathematical correlation and clinical implications. Exp Oncol 28:75–79

    CAS  PubMed  Google Scholar 

  103. Machens A, Hinze R, Thomusch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28

    PubMed  Google Scholar 

  104. Ito Y, Tomoda C, Uruno T et al (2004) Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 28:498–501

    PubMed  Google Scholar 

  105. Kouvaraki MA, Shapiro SE, Fornage BD et al (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134:946–954

    PubMed  Google Scholar 

  106. Gemsenjager E, Perren A, Seifert B et al (2003) Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 197:182–190

    PubMed  Google Scholar 

  107. Wang TS, Dubner S, Sznyter LA, Heller KS (2004) Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg 130:110–113

    PubMed  Google Scholar 

  108. Kupferman ME, Patterson M, Mandel SJ et al (2004) Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 130:857–860

    PubMed  Google Scholar 

  109. Kupferman ME, Patterson DM, Mandel SJ et al (2004) Safety of modified radical neck dissection for differentiated thyroid carcinoma. Laryngoscope 114:403–406

    PubMed  Google Scholar 

  110. Goropoulos A, Karamoshos K, Christodoulou A et al (2004) Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg 28:1275–1281

    PubMed  Google Scholar 

  111. Sawka AM, Thephamongkhol K, Brounwers M et al (2004) Clinical review 170: a systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676

    CAS  PubMed  Google Scholar 

  112. Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229–1242

    PubMed  Google Scholar 

  113. Momesso DP, Vaisman F et al (2012) Small differentiated thyroid cancer: Time to reconsider clinical management and treatment. Surg Oncol 21:257–262

    PubMed  Google Scholar 

  114. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH (1992) Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75:344–350

    CAS  PubMed  Google Scholar 

  115. Tsang RW, Brierley JD, Simpson WJ et al (1998) The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82:375–388

    CAS  PubMed  Google Scholar 

  116. Farahati J, Reiners C, Stuscke M et al (1996) Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77:172–180

    CAS  PubMed  Google Scholar 

  117. Luster M, Clarke SE, Dietlein M et al (2008) Guidelines for radioiodine therapy for differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959

    CAS  PubMed  Google Scholar 

  118. Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of follicular epithelium. Eur J Endocrinol 154:787–803

    CAS  PubMed  Google Scholar 

  119. Genevieve R, Tuttle RM (2011) Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. Semin Nucl Med 41:89–95

    Google Scholar 

  120. Caminha LS, Momesso DP, Vaisman F et al (2013) Long-term follow-up of patients with differentiated thyroid cancer who had negative 131I whole body scan at first evaluation after treatment. Clin Nucl Med 38:765–769

    PubMed  Google Scholar 

  121. Garas G, Jarral O, Tolley N et al (2013) Is there a survival benefit from life-long follow-up after treatment for differentiated thyroid cancer? Int J Surg 11(2):116–121

    PubMed  Google Scholar 

  122. Norden MM, Larsson F, Tedelind S et al (2007) Down-regulation of sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res 67:7512–7517

    CAS  PubMed  Google Scholar 

  123. Grigsby PW, Baglan K, Siegel BA (1999) Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 85:945–951

    CAS  PubMed  Google Scholar 

  124. Lee JW, Lee SM, Lee DH, Kim YJ (2013) Clinical utility of 18 F-FDG PET/CT concurrent with 131I-therapy in intermediate-to-high risk patients with differentiated thyroid cancer: Dual-center experience with 286 patients. J Nucl Med 54:1230–1236

    CAS  PubMed  Google Scholar 

  125. Spencer CA, Lopresti JS (2008) Measuring thyroglobulin and thyroglobulin antibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 4:223–233

    CAS  PubMed  Google Scholar 

  126. Spencer CA, Bergoglio LM, Kazarosyan M et al (2005) Clinical impact of thyroglobulin(Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:5566–5575

    CAS  PubMed  Google Scholar 

  127. Song HJ, Xue YL, Xu YH et al (2011) Rare metastases of differentiated thyroid carcinoma: pictorial review. Endocr Relat Cancer 18:R165–R174

    CAS  PubMed  Google Scholar 

  128. Ulger Z, Karaman N, Pişkinpaşa SH et al (2006) Endobronchial metastases of thyroid follicular carcinoma. J Natl Med Assos 98:803–806

    Google Scholar 

  129. Ruegemer JJ, Hay ID, Bergstralh EJ et al (1988) Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501–508

    CAS  PubMed  Google Scholar 

  130. Samaan NA, Schultz PN, Haynie TP et al (1985) Pulmonary metastases of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60:376–380

    CAS  PubMed  Google Scholar 

  131. Kim WG, Kim EY, Kim TY et al (2009) Redifferentiation therapy with 13-cis retinoic acid in radioiodine resistant thyroid cancer. Endocr J 56:105–112

    CAS  PubMed  Google Scholar 

  132. Kıratlı PO, Volkan-Salancı B, Günay EC et al (2013) Thyroid cancer in pediatric age group: an institutional experience and review of the literature. J Pediatr Hematol Oncol 35:93–97

    PubMed  Google Scholar 

  133. Molinaro E, Giani C, Agate L et al (2013) Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab 98:2693–2700

    CAS  PubMed  Google Scholar 

  134. Pacini F, Ito Y, Luster M (2012) Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 7:541–554

    CAS  Google Scholar 

  135. Wong KP, Lang BHH (2012) New molecular targeted therapy and redifferentiation therapy for radioiodine refractory advanced papillary thyroid carcinoma: literature review. Journal of Thyroid Research, Article ID:818204, 9 pages, http://dx.doi.org/10.1155/2012/818204

  136. Brose MS, Nutting C, Jarzab B, et al (2013) Sorafenib in locally advanced or metastatic patients with radioactive iodine refractory differentiated thyroid cancer: the phase III DECISION trial. J Clin Oncol 31 (Suppl):abstr 4

    Google Scholar 

  137. Filetti S, Bidart JM, Arturi F et al (1999) Sodium/iodide symporter: A key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141:443–457

    CAS  PubMed  Google Scholar 

  138. Grüning T, Tiepolt C, Zöphel K et al (2003) Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endocrinol 148:395–402

    PubMed  Google Scholar 

  139. Short SC, Suovuori A, Cook G et al (2004) A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol 16:569–574

    CAS  Google Scholar 

  140. Simon D, Körber C, Krausch M et al (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: results of a pilot study. Eur J Nucl Med Mol Imaging 29:775–782

    CAS  PubMed  Google Scholar 

  141. Oh SW, Moon SH, Cho BY et al (2011) Combined therapy with I-131 and retinoic acid in Korean patients with radioiodine refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging 38:1798–1805

    CAS  PubMed  Google Scholar 

  142. Kebebew E, Lindsay S, Clark OH et al (2009) Results of rosiglitazone therapy in patients with thyroglobulin positive and radioiodine negative advanced thyroid cancer. Thyroid 19:953–956

    CAS  PubMed  Google Scholar 

  143. Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453–464

    PubMed  Google Scholar 

  144. Santarpia L, El-Naggar AK, Cote GJ et al (2008) Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278–284

    CAS  PubMed  Google Scholar 

  145. Smallridge RC, Ain KB, Asa SL et al (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104–1139

    PubMed  Google Scholar 

  146. McIver B, Hay ID, Giuffrida DF et al (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028–1034

    CAS  PubMed  Google Scholar 

  147. Chen J, Tward JD, Shrieve DC, Hitchcock YJ (2008) Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983–2002. Am J Clin Oncol 31:460–464

    CAS  PubMed  Google Scholar 

  148. Passler C, Scheuba C, Prager G et al (1999) Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 384:284–293

    CAS  PubMed  Google Scholar 

  149. Tan RK, Finley RK 3rd, Driscoll D et al (1995) Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 17:41–47

    CAS  PubMed  Google Scholar 

  150. Junor EJ, Paul J, Reed NS (1992) Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18:83–88

    CAS  PubMed  Google Scholar 

  151. Pierie JP, Muzikansky A, Gaz RD et al (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57–64

    PubMed  Google Scholar 

  152. Swaak-Kragten AT, de Wilt JH, Schmitz PI et al (2009) Multimodality treatment for anaplastic thyroid carcinoma-treatment outcome in 75 patients. Radiother Oncol 92:100–104

    PubMed  Google Scholar 

  153. Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2342

    CAS  PubMed  Google Scholar 

  154. Goutsouliak V, Hay JH (2005) Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based study. Clin Oncol (R Coll Radiol) 17:75–78

    CAS  Google Scholar 

  155. Brignardello E, Gallo M, Baldi I et al (2007) Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156:425–430

    CAS  PubMed  Google Scholar 

  156. Kihara M, Miyauchi A, Yamauchi A, Yokomise H (2004) Prognostic factors of anaplastic thyroid carcinoma. Surg Today 34:394–398

    PubMed  Google Scholar 

  157. De Crevoisier R, Baudin E, Bachelot A et al (2004) Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60:1137–1143

    PubMed  Google Scholar 

  158. Schlumberger M, Parmentier C, Delisle MJ et al (1991) Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564–566

    CAS  PubMed  Google Scholar 

  159. Shimaoka K, Schoenfeld DA, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160

    CAS  PubMed  Google Scholar 

  160. Mooney CJ, Nagaiah G, Fu P et al (2009) A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule1 with outcome. Thyroid 19:233–240

    PubMed Central  CAS  PubMed  Google Scholar 

  161. Sosa JA, Balkissoon J, Lu SP et al (2012) Thyroidectomy followed by fosbretabulin(CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery 152:1078–1087

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Instıtute of Oncology, Ankara, Turkey

    E. Nilüfer Güler MD (Professor Emeritus)

  2. Department of Nuclear Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey

    Murat Fani Bozkurt MD, FEBNM

  3. Breast and Endocrine Surgery, Ankara Guven Hospital, Ankara, Turkey

    Serdar Ozbas MD, FEBS

  4. Department of Medical Oncology, Hacettepe University Institute of Cancer, Ankara, Turkey

    Suayib Yalcin MD

Authors
  1. E. Nilüfer Güler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murat Fani Bozkurt MD, FEBNM
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serdar Ozbas MD, FEBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suayib Yalcin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Nilüfer Güler MD .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Güler, E.N., Bozkurt, M.F., Ozbas, S., Yalcin, S. (2015). Thyroid Cancer. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation